fluticasone has been researched along with Psoriasis* in 10 studies
8 trial(s) available for fluticasone and Psoriasis
Article | Year |
---|---|
Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas.
Facial and intertriginous skin is more susceptible to corticosteroid-induced atrophy. Dosing regimens are needed for long-term management of corticosteroid-sensitive sites.. The safety and efficacy of 0.005% fluticasone propionate ointment were assessed in the short-and long-term management of moderate to severe psoriasis of facial and intertriginous areas compared with nonfacial, nonintertriginous areas.. Affected areas in 20 patients with psoriasis were treated twice daily for 2 weeks, then once daily for 2 consecutive days every week for 8 more weeks.. More than 50% improvement occurred after 2 weeks (day 15) in 100% of facial and intertriginous lesions and was maintained during long-term therapy in more than 85% of facial and intertriginous lesions. More than 50% improvement for nonfacial, nonintertriginous areas reached only 80% by day 15. Recurrence rates for facial and intertriginous areas were lower than in the nonfacial, nonintertriginous areas. Skin atrophy and telangiectasia did not occur. Facial and intertriginous sites responded more quickly to topical fluticasone propionate ointment than nonfacial, nonintertriginous skin.. Limited application of fluticasone propionate ointment over a period of 10 weeks is effective and delays lesion recurrence without causing skin atrophy in patients with moderate to severe psoriasis in areas at risk for corticosteroid application, such as facial and intertriginous areas. Topics: Administration, Topical; Adult; Aged; Androstadienes; Anti-Inflammatory Agents; Dermatologic Agents; Drug Administration Schedule; Facial Dermatoses; Female; Fluticasone; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Psoriasis; Recurrence; Treatment Outcome | 2001 |
A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis.
The efficacy, safety, and tolerability of twice-daily fluticasone propionate (Cutivate) cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, were compared in 125 patients with moderate-to-severe psoriasis in a 4-week, multicenter, double-blind, randomized, active-control study. Clinical assessments of response to therapy, made at weekly intervals, included physicians' gross assessment of clinical response, improvement in signs and symptoms, and patients' assessment of treatment effects. Based on physicians' gross assessment, fluticasone propionate cream was superior to hydrocortisone-17-butyrate cream at day 22 (after 3 weeks' treatment) and at the end-of-treatment visit (P < .05). Cleared, excellent, or good end-of-treatment response rates were 50/63 (79%) for fluticasone propionate compared with 41/60 (68%) for hydrocortisone-17-butyrate. Adverse events were limited to mild-to-moderate pruritus with fluticasone propionate (3.2%) and hydrocortisone-17-butyrate (1.7%) and mild skin warmth with hydrocortisone-17-butyrate (1.7%). Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluticasone; Humans; Hydrocortisone; Male; Middle Aged; Ointments; Psoriasis; Skin | 2001 |
[The therapeutic activity of Cutivate in the treatment of inflammatory skin diseases].
Topics: Administration, Topical; Adult; Androstadienes; Anti-Inflammatory Agents; Child; Chronic Disease; Dermatitis, Atopic; Dermatologic Agents; Fluticasone; Glucocorticoids; Humans; Psoriasis | 2000 |
[Fluticasone propionate, corticosteroid for topical treatment].
The aim of this study was to evaluate the usefulness of fluticasone propionate in various dermatoses and to present the data to non-dermatologists. The study was performed at the Department of Dermatology, University School of Medicine in PoznaĆ. The studied group consisted of 40 cases of various types of eczema, psoriasis vulgaris, DLE, photodermatoses and morphea. Fluticasone propionate cream or ointment was applied to lesional skin twice daily for 7-19 days. Acute eczematous skin lesions significantly improved after the first seven days of treatment, whereas in patients with chronic eczema the good therapeutic results were observed after 14-19 days. Fluticasone propionate was also effective in the treatment of DLE and photodermatoses. Topics: Administration, Topical; Adolescent; Adult; Aged; Androstadienes; Anti-Inflammatory Agents; Drug Administration Schedule; Eczema; Female; Fluticasone; Glucocorticoids; Humans; Male; Middle Aged; Photosensitivity Disorders; Proteus Infections; Proteus vulgaris; Psoriasis; Scleroderma, Localized; Skin Diseases | 1998 |
Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis.
The efficacy, safety, and tolerability of the mid-potency corticosteroid, fluticasone propionate ointment, 0.005%, were compared with those of a high-potency corticosteroid, betamethasone-17,21-dipropionate ointment, 0.05%, in a twelve-week randomized, double-blind, parallel-group, multicenter study of seventy-four patients with moderate-to-severe psoriasis. Efficacy was evaluated for four weeks; safety was evaluated over a twelve-week period. Fluticasone ointment, 0.005%, was not significantly different from betamethasone ointment, 0.05%, at day 15 (P = 0.147), at the end of treatment analysis (P = 0.245), or at day 29 (P = 0.154). Neither medication resulted in any abnormal laboratory values over the twelve-week study period, including plasma cortisol levels. Both medications were well tolerated. Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents; Betamethasone; Double-Blind Method; Female; Fluticasone; Humans; Hydrocortisone; Male; Middle Aged; Ointments; Psoriasis | 1996 |
A comparison of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, in the treatment of psoriasis.
The efficacy and safety of twice-daily topical application of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, were compared in 113 adult patients with moderate-to-severe psoriasis in a multicenter, double-blind, randomized, parallel study. The majority of patients had psoriatic involvement of long duration over a large body surface area (mean, 17%). The following efficacy assessments were made at weekly intervals for up to four weeks following initiation of treatment: physician's gross assessment of clinical response of the target lesion; severity of psoriatic signs and symptoms; and patients' assessment of treatment effects. Safety was assessed by monitoring and reporting any adverse events that occurred during the study. Fluticasone propionate ointment, 0.005%, was found to be therapeutically superior to hydrocortisone-17-butyrate ointment, 0.1%, as well as safe and well tolerated. Its onset of action was rapid and no systemic adverse effects occurred. Overall patients experienced progressive improvement with fluticasone propionate ointment, 0.005%. Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluticasone; Humans; Hydrocortisone; Male; Middle Aged; Ointments; Psoriasis | 1996 |
Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis.
Investigators conducted two double-blind, randomized, parallel-group trials to compare the efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Up to 100 gm/week of the study medication was applied topically to affected areas of the body twice daily for up to four consecutive weeks. Efficacy and safety were evaluated after seven, fourteen, twenty-one, and twenty-eight days of treatment. The data from the participating sites show that fluticasone propionate cream, 0.05%, was as efficacious as betamethasone valerate cream. Investigators found no statistically significant differences between the two products by any of the three variables used to gauge efficacy (P > 0.05). Drug-related adverse events were few and mild. These findings support the conclusion that fluticasone propionate cream, 0.05%, is effective and well tolerated when used to treat moderate-to-severe psoriasis and is comparable to a widely used midpotency topical steroid. Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents; Betamethasone Valerate; Double-Blind Method; Female; Fluticasone; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Psoriasis | 1996 |
Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis.
Two multicenter, double-blind, randomized, vehicle-controlled parallel-group trials involving 388 patients were conducted to compare the efficacy and safety of fluticasone propionate 0.005% ointment to those of its vehicle in the treatment of moderate-to-severe psoriasis. The study medication (up to 100 gm/week) was applied topically to the affected target areas of the body twice daily for up to four consecutive weeks. Efficacy and safety were evaluated after one, two, three, and four weeks of treatment. In both studies, fluticasone ointment was clearly shown to be superior to vehicle throughout the four weeks of treatment. At the end of the treatment period, the superiority of fluticasone ointment was statistically significant for all efficacy measures. At the end of study 1, the skin of ten of eighty-eight patients (11%) who received fluticasone were rated as cleared by the investigators and fifty (57%) were rated as excellent or good. Of those who received vehicle, the skin of one of ninety (1%) was rated cleared and twenty-five (28%) were rated excellent or good. In study 2, the skin of three of 105 (3%) patients who received fluticasone were rated as cleared and sixty-nine (66%) were rated as excellent or good at the end of the study. Of those who were treated with vehicle, no patient's skin was rated cleared and thirty of 100 (30%) were rated excellent or good. Adverse events were few and mild. The most common drug-related adverse events were burning and pruritus at the site of application, which occurred in 6% of both the fluticasone-treated patients and those who received vehicle. These findings support the conclusion that fluticasone, 0.005%, ointment is clinically superior to its vehicle in the treatment of psoriasis. Topics: Administration, Topical; Adolescent; Adult; Aged; Androstadienes; Anti-Inflammatory Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluticasone; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Psoriasis; Safety | 1996 |
2 other study(ies) available for fluticasone and Psoriasis
Article | Year |
---|---|
Psoriasis of the lips: a rare entity.
Topics: Adult; Androstadienes; Female; Fluticasone; Humans; Lip Diseases; Mometasone Furoate; Ointments; Prednisolone; Pregnadienediols; Psoriasis; Treatment Outcome | 2007 |
Inhaled steroids and psoriasis.
Topics: Androstadienes; Anti-Asthmatic Agents; Bronchodilator Agents; Budesonide; Female; Fluticasone; Humans; Nebulizers and Vaporizers; Pregnenediones; Psoriasis; Recurrence | 1995 |